

han Yao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4028292/publications.pdf>

Version: 2024-02-01

15
papers

1,007
citations

933447

10
h-index

1125743

13
g-index

16
all docs

16
docs citations

16
times ranked

1631
citing authors

#	ARTICLE	IF	CITATIONS
1	Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1. <i>Fundamental Research</i> , 2023, 3, 647-654.	3.3	0
2	A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. <i>RSC Chemical Biology</i> , 2021, 2, 192-205.	4.1	26
3	Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity. <i>Oncogene</i> , 2021, 40, 1128-1146.	5.9	22
4	An unexpected role for p53 in regulating cancer cellâ€™intrinsic PD-1 by acetylation. <i>Science Advances</i> , 2021, 7, .	10.3	32
5	THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. , 2021, 9, e002443.		16
6	Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 295-324.	1.6	8
7	Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. <i>Nature Biomedical Engineering</i> , 2019, 3, 306-317.	22.5	279
8	HIP1R targets PD-L1 to lysosomal degradation to alter T cellâ€™mediated cytotoxicity. <i>Nature Chemical Biology</i> , 2019, 15, 42-50.	8.0	189
9	A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. <i>Cell Chemical Biology</i> , 2018, 25, 761-774.e5.	5.2	17
10	Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. <i>Frontiers in Pharmacology</i> , 2018, 9, 536.	3.5	160
11	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1774.	4.8	125
12	ASAP3 regulates microvilli structure in parietal cells and presents intervention target for gastric acidity. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17003.	17.1	2
13	PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. <i>Oncolmmunology</i> , 2017, 6, e1327494.	4.6	52
14	Rise of PDâ€™L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. <i>Journal of Digestive Diseases</i> , 2017, 18, 574-581.	1.5	70
15	Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation. <i>Gastrointestinal Tumors</i> , 2017, 4, 1-10.	0.7	0